Dovonex, a topical vitamin D derivative, reduces excessive skin cell production and therefore helps improve the symptoms of psoriasis. It is sold under the brand name Daivonex in certain European, South American, and Asian markets. Although the current availability of various formulations differs by market, Dovonex is manufactured as an ointment or a cream for psoriasis plaques on the body and as a lotion (solution) for scalp psoriasis.
While Dovonex (calcipotriol; Leo Pharma) was historically the most popular topical vitamin derivative in the psoriasis market, owing to its proven efficacy and safety, its patient share has seen a steady decline since 2007 owing to expiries of its molecule and ointment formulation patents. The strategic 2001 launch of Dovobet, a combination of calcipotriol and betamethasone, helped Leo Pharma retain a significant proportion of patient share lost to generics of its Dovonex ointment.
TABLE OF CONTENTS
4 PRODUCT PROFILES
4 Dovonex : Psoriasis
LIST OF FIGURES
9 Figure 1: Dovonex for psoriasis – SWOT analysis
10 Figure 2: Datamonitor Healthcare’s drug assessment summary of Dovonex in psoriasis
10 Figure 3: Datamonitor Healthcare’s drug assessment summary of Dovonex in psoriasis
LIST OF TABLES
4 Table 1: Dovonex drug profile
7 Table 2: Dovonex pivotal trial data in psoriasis
Datamonitor Healthcare is part of Pharma intelligence
Datamonitor Healthcare is a trading division of Datamonitor Limited, a company registered in England and Wales with company number 2306113 whose registered office is 5 Howick Place, London, SW1P 1WG. VAT GB365462636. Datamonitor Limited is part of Informa PLC.
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726